Reference
·Supporting source
Thailand pharmaceutical manufacturer revenue share (2024)
GPO ~16%
Government Pharmaceutical Organization (GPO), the state-owned manufacturer that supplies the Universal Coverage scheme and operates the largest NLEM-aligned generic portfolio, leads domestic pharma manufacturing at roughly 16% of factory-gate revenue per PReMA 2024 estimates. Mega Lifesciences sits second at approximately 12%, Olic Thailand third at 9%, and Bangkok Drug fourth at 7%. The top-10 manufacturers control about 60% of domestic factory-gate revenue. The remainder is fragmented across roughly 170 GMP-certified Thai-licensed manufacturers, the bulk of which run sub-scale generic, OTC, and herbal/cosmetic SKUs.
Figure in context
Government Pharmaceutical Organization (GPO), the state-owned manufacturer that supplies the Universal Coverage scheme and operates the largest NLEM-aligned generic portfolio, leads domestic pharma manufacturing at roughly 16% of factory-gate revenue per PReMA 2024 estimates. Mega Lifesciences sits second at approximately 12%, Olic Thailand third at 9%, and Bangkok Drug fourth at 7%. The top-10 manufacturers control about 60% of domestic factory-gate revenue. The remainder is fragmented across roughly 170 GMP-certified Thai-licensed manufacturers, the bulk of which run sub-scale generic, OTC, and herbal/cosmetic SKUs.
Interpretation notes
What this tells you
Government Pharmaceutical Organization (GPO), the state-owned manufacturer that supplies the Universal Coverage scheme and operates the largest NLEM-aligned generic portfolio, leads domestic pharma manufacturing at roughly 16% of factory-gate revenue per PReMA 2024 estimates. Mega Lifesciences sits second at approximately 12%, Olic Thailand third at 9%, and Bangkok Drug fourth at 7%. The top-10 manufacturers control about 60% of domestic factory-gate revenue. The remainder is fragmented across roughly 170 GMP-certified Thai-licensed manufacturers, the bulk of which run sub-scale generic, OTC, and herbal/cosmetic SKUs.
What not to do with it
Values in percent of domestic factory-gate revenue. Top-10 cumulative share approximately 60%.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand pharmaceutical manufacturing factory-gate revenue (2020-2024)
Thai FDA, Pharmaceutical Research and Manufacturers Association of Thailand, Krungsri Research, Bangkok Post pharma coverage
Thailand pharmaceutical generic vs branded mix (2024)
PReMA, IQVIA Thailand, Thai FDA, Government Pharmaceutical Organization
BOI Future Medicine approved projects (2020-2024)
Thailand Board of Investment, BOI Future Medicine sector briefing, NESDC
Thailand FDA GMP-certified pharmaceutical facility count (2024)
Thai FDA Drug Control Division, PIC/S accession documentation, PReMA, industry estimates
Siam Bioscience vaccine output capacity (2024)
Siam Bioscience disclosures, PReMA, Bangkok Post pharma coverage, WHO prequalification listing
Thailand pharma facilities with EU GMP cross-certification (2024)
Thai FDA, EudraGMDP database, PReMA, operator disclosures
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.